Document is current
Any future updates will be listed below
-
Authors
Roberts, Mark E.
Proskorovsky, Irina
Guyot, Patricia
Shukla, Pragya
Thibault, Nathan
Hamed, Alaa
Pulikottil-Jacob, Ruth
O’Callaghan, Lasair
Pollissard, Laurence
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 26 November 2024
Accepted: 30 June 2025
First Online: 8 September 2025
Declarations
:
: Mark E. Roberts is part of the Advisory Boards for Amicus Therapeutics, BioMarin, Sanofi and Spark Therapeutics. Irina Proskorovsky and Pragya Shukla are employees of Evidera and may hold shares in the company. Patricia Guyot, Nathan Thibault, Alaa Hamed, Lasair O’Callaghan and Laurence Pollissard are employees of Sanofi and may hold stocks and/or stock options in the company. Ruth Pulikottil-Jacob was an employee of Sanofi at the time of study conduct. Her current affiliation, unrelated to this work is Cepheid UK, High Wycombe, UK.
: The study protocols for the studies included in the ITC were reviewed and approved by appropriate ethics committees and/or institutional review boards and conducted in accordance with the Declaration of Helsinki and the International Council for Harmonisation Guidelines for Good Clinical Practice. Written informed consent was obtained from participants.
